Following the company’s major milestone of receiving CE Mark Certification for its HFX iQ spinal cord stimulation (SCS) device in Europe, shares of Nevro Corp. (NASDAQ: NVRO) jumped 3.01% today to $5.48. This certification supports Nevro’s strategic objective of growing its market presence by enabling it to sell its HFX iQ system in European nations that accept the CE mark.
Presenting AI-Powered, Tailored Pain Management
The first artificial intelligence (AI)-powered SCS device created especially for high-frequency (10 kHz) treatment is the HFX iQ system. In contrast to traditional SCS systems, HFX iQ provides a highly customized pain relief experience by utilizing cloud-based data insights. The system is an innovative approach to chronic pain reduction since it analyzes continuous patient data and adjusts in real-time to match specific pain management demands.
Using Data-Driven Therapy to Improve Patient Experience
The HFX iQ system, which was created after more than ten years of patient data and result analysis, attempts to enhance patient quality of life by lowering the number of needless hospital stays and eliminating the need for frequent in-person programming modifications.
Its AI-driven algorithms provide tailored recommendations based on patient feedback, collected through the HFX App. This personalized approach enables patients to manage their pain more independently, potentially reducing healthcare costs and enhancing resource efficiency.
Comprehensive Pain Relief with HFX iQ Technology
The HFX iQ system offers indication-specific algorithms for various chronic pain conditions, including back and leg pain, painful diabetic neuropathy, and chronic upper limb and neck pain.
It is the only CE-marked SCS system that offers 10 kHz Therapy across all major SCS indications, addressing not only pain relief but also improving overall patient outcomes. This tailored functionality allows patients to receive a high level of personalized care, empowering them to regain control over their lives with less dependence on clinical interventions.
Nevro is Setting a New Standard
By integrating AI and real-time patient feedback, Nevro’s HFX iQ system represents a new era of patient-centered care in pain management. Already FDA-approved in the United States, NVRO plans to launch the HFX iQ system in select European countries in early 2025, marking a critical step in Nevro’s global expansion. With its focus on personalized, adaptive therapy, HFX iQ is redefining possibilities for long-term, effective pain relief.